CIK 0001933414 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Mineralys Therapeutics, Inc.
Sign in to watch- Ticker
- MLYS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 841966887
- Phone
- (888) 378-6240
- Business address
- 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR, PA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,403,032
- in 5 filings, $2.4M under 10b5-1 plans
Net −$5,403,032. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 62 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-12 | Rodman David Malcom Chief Medical Officer | Option exercise 10b5-1 | +6,348 | $1.08 | $7K | 113,017 |
| 2025-06-12 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −6,348 | 95,229 | ||
| 2025-05-14 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −11,366 | $15.29 | $174K | 106,669 |
| 2025-05-12 | Rodman David Malcom Chief Medical Officer | Option exercise 10b5-1 | +6,349 | $1.08 | $7K | 118,035 |
| 2025-05-12 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −6,349 | 101,577 | ||
| 2025-04-14 | Rodman David Malcom Chief Medical Officer | Option exercise 10b5-1 | +6,348 | $1.08 | $7K | 123,052 |
| 2025-04-14 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −2,966 | $13.69 | $41K | 120,086 |
| 2025-04-14 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −8,400 | $14.83 | $125K | 111,686 |
| 2025-04-14 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −6,348 | 107,926 | ||
| 2025-04-11 | Levy Adam Scott CFO and Secretary | Sale 10b5-1 | −10,757 | $12.06 | $130K | 215,340 |
| 2025-04-11 | Congleton Jon Chief Executive Officer | Sale 10b5-1 | −15,319 | $12.19 | $187K | 862,289 |
| 2025-04-01 | Rodman David Malcom Chief Medical Officer | Option exercise 10b5-1 | +1,606 | $1.08 | $2K | 172,475 |
| 2025-04-01 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −30,574 | $15.00 | $459K | 141,901 |
| 2025-04-01 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −2,791 | $16.02 | $45K | 139,110 |
| 2025-04-01 | Rodman David Malcom Chief Medical Officer | Sale 10b5-1 | −22,406 | $16.77 | $376K | 116,704 |
| 2025-04-01 | Rodman David Malcom Chief Medical Officer | Option exercise · Stock Option 10b5-1 | −1,606 | 114,274 | ||
| 2025-03-13 | Slingsby Brian Taylor Director | Purchase | +259,259 | $13.50 | $3.5M | 8,903,838 |
| 2025-03-13 | Samsara BioCapital GP, LLC 10% owner | Purchase | +600,000 | $13.50 | $8.1M | 5,674,916 |
| 2025-03-13 | AKKARAJU SRINIVAS Director | Purchase | +600,000 | $13.50 | $8.1M | 5,674,916 |
| 2025-03-13 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +1,296,296 | $13.50 | $17.5M | 4,280,051 |
Page 14 of 17 · 321 trades